BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37649946)

  • 1. Histopathologic and Molecular Features of Cutaneous Melanoma in a Moroccan Population.
    Tahiri Elousrouti L; Hammas N; Fadlallah I; Elberdai S; Amaadour I; Elloudi S; Elmernissi FZ; Elidrissi M; Hassani W; Alami B; Chbani L
    Cureus; 2023 Jul; 15(7):e42691. PubMed ID: 37649946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does the morphology of cutaneous melanoma help to explain the international differences in survival? Results from 1 578 482 adults diagnosed during 2000-2014 in 59 countries (CONCORD-3).
    Di Carlo V; Stiller CA; Eisemann N; Bordoni A; Matz M; Curado MP; Daubisse-Marliac L; Valkov M; Bulliard JL; Morrison D; Johnson C; Girardi F; Marcos-Gragera R; Šekerija M; Larønningen S; Sirri E; Coleman MP; Allemani C;
    Br J Dermatol; 2022 Sep; 187(3):364-380. PubMed ID: 35347700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity and Usefulness of VE1 Immunohistochemical Staining in Acral Melanomas with
    Suh MS; Choi YD; Lee JB; Lee SC; Won YH; Yun SJ
    Ann Dermatol; 2018 Oct; 30(5):556-561. PubMed ID: 33911478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Survival analysis in patients with cutaneous malignant melanoma].
    Radović-Kovacević V; Pekmezović T; Adanja B; Jarebinski M; Marinković J; Tomin R
    Srp Arh Celok Lek; 1997; 125(5-6):132-7. PubMed ID: 9265233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF Mutation Analysis in Primary Acral Melanoma of 41 Cases from South of Iran.
    Sari Aslani F; Safaee A; Akbarzadeh Jahromi M; Karami L
    Iran J Pathol; 2021; 16(4):370-375. PubMed ID: 34567185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary cutaneous malignant melanoma in Ethiopian patients histopathologic study of 50 cases from Tikur Anbessa Hospital.
    Legesse TB; Schneider J
    Ethiop Med J; 2011 Oct; 49(4):313-22. PubMed ID: 23409396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF V600E mutation as a prognostic factor in cutaneous melanoma patients.
    Tas F; Erturk K
    Dermatol Ther; 2020 Mar; 33(2):e13270. PubMed ID: 32061008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic characteristics and response to systemic therapies of acral lentiginous melanoma at a tertiary care center-a retrospective review.
    Jamerson T; Rebecca VW; Aguh C
    J Natl Med Assoc; 2022 Feb; 114(1):7-11. PubMed ID: 34509302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary Cutaneous Melanoma in a Tertiary Hospital: A Retrospective Study.
    Sharma N; Adhikari RC; Sayami G
    J Nepal Health Res Counc; 2021 Sep; 19(2):300-304. PubMed ID: 34601520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival.
    Ito T; Kaku-Ito Y; Murata M; Furue K; Shen CH; Oda Y; Furue M
    J Clin Med; 2020 Mar; 9(3):. PubMed ID: 32143442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological Profile of a Cohort of Patients With Malignant Melanoma in the United Kingdom.
    Haroon S; Vithanage I; Rashid K; Aslam M; Elmahdy H; Zia S; Malik UA; Irfan M; Hashmi AA
    Cureus; 2023 Jun; 15(6):e39874. PubMed ID: 37404434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limb melanomas: acral melanomas have worse survival.
    Tas F; Erturk K
    J Dermatolog Treat; 2022 May; 33(3):1630-1637. PubMed ID: 33470132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acral lentiginous melanoma: histopathological prognostic features of 121 cases.
    Phan A; Touzet S; Dalle S; Ronger-Savlé S; Balme B; Thomas L
    Br J Dermatol; 2007 Aug; 157(2):311-8. PubMed ID: 17596173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acral cutaneous melanoma in a Spanish Caucasian population.
    Avilés-Izquierdo JA; Longo-Imedio MI; Lázaro-Ochaita P
    Melanoma Res; 2010 Jun; ():. PubMed ID: 20585270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [ Spectrum of oncogene mutations is different in melanoma subtypes].
    Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
    Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenetic Implications of BRAF Mutation Distribution in Stage IV Melanoma Patients.
    Baiter M; Schuler G; Hartmann A; Schneider-Stock R; Heinzerling L
    Dermatology; 2015; 231(2):127-33. PubMed ID: 26138035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF, KIT, NRAS, GNAQ and GNA11 mutation analysis in cutaneous melanomas in Turkish population.
    Yilmaz I; Gamsizkan M; Kucukodaci Z; Berber U; Demirel D; Haholu A; Narli G
    Indian J Pathol Microbiol; 2015; 58(3):279-84. PubMed ID: 26275246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma.
    Greaves WO; Verma S; Patel KP; Davies MA; Barkoh BA; Galbincea JM; Yao H; Lazar AJ; Aldape KD; Medeiros LJ; Luthra R
    J Mol Diagn; 2013 Mar; 15(2):220-6. PubMed ID: 23273605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective study of malignant melanoma from a tertiary care centre in Saudi Arabia from 2004 to 2016.
    Alshedoukhy A; Cahusac P; Kashir J; Alkhawaja FH; Tulbah AMM; Anwar K
    Clin Transl Oncol; 2020 May; 22(5):663-669. PubMed ID: 31256363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical Analysis of BRAF (V600E) Mutation and P16 Expression in Malignant Melanoma in Lagos, Nigeria: A 10-Year Retrospective Study.
    Obadofin O; Badmos K; Orsi N; Bipin M; Rotimi O; Banjo A
    J Skin Cancer; 2019; 2019():1628247. PubMed ID: 31139472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.